TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05775289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive IV paclitaxel Q3W for four 21-day cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Participants will receive IV paclitaxel Q3W for four 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Participants will receive IV pemetrexed Q3W until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Participants will receive IV pemetrexed Q3W until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive IV carboplatin Q3W for four 21-day cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Participants will receive IV carboplatin Q3W for four 21-day cycles
Study: NCT06051227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate
Description: Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
Study: NCT06515990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM005
Description: An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM005
Description: An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM005
Description: An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM005
Description: An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM005
Description: An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DM005
Description: An IV infusion of DM005 will be administrated approximately 30-60 min on D1 once Q3W.
Study: NCT05076409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: Period 1 and period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluconazole
Description: Period 2
Study: NCT04850391

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile app
Description: To compare changes induced by the movile app intervention among the three study groups

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile app
Description: To compare changes induced by the movile app intervention among the three study groups

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobile app
Description: To compare changes induced by the movile app intervention among the three study groups
Study: NCT06104878

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention will be administered in this study.

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention will be administered in this study.
Study: NCT04945850

Intervention type: PROCEDURE
Intervention: routine care intraocular sx
Description: Fluid was collected during routine intraocular surgery

Intervention type: PROCEDURE
Intervention: routine care intraocular sx
Description: Fluid was collected during routine intraocular surgery
Study: NCT05190354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xtremity Polymer Prosthetic Socket
Description: Subjects with transtibial unilateral or bilateral amputation who have experience using a standard carbon fiber or high temperature thermoplastic prosthetic socket will be evaluated and fitted with a below knee prosthesis socket
Study: NCT06420856

Intervention type: OTHER
Intervention: Assessment of the musculoskeletal system and its functions
Description: Measurement of sub sole pressure sense, light touch sense, vibration sense and two-point discrimination sense. will be evaluated with. For the evaluation of proprioception, active joint position sense technique was used in plantar flexion (PF): 7°, 14° and 21°; In dorsiflexion (DF), 7° target angles will be used. An Dr. Goniometer will be used to determine target angles. To measure plantarflexion and dorsiflexion muscular strength and endurance will be used with the isokinetic system. Weight-Bearing Lunge test will be used to evaluate ankle mobility. For balance assessment, the Modified Star Excursion Balance Test will be measured using the anterior, posteromedial and posterolateral directions. American Orthopedic Foot and Ankle Society midfoot score and foot and ankle functions Rating Foot and Ankle Outcome Score , which are subjective evaluation methods, will be used to determine the functional level. A heel lift test will be performed to evaluate physical performance.

Intervention type: OTHER
Intervention: Assessment of the musculoskeletal system and its functions
Description: Measurement of sub sole pressure sense, light touch sense, vibration sense and two-point discrimination sense. will be evaluated with. For the evaluation of proprioception, active joint position sense technique was used in plantar flexion (PF): 7°, 14° and 21°; In dorsiflexion (DF), 7° target angles will be used. An Dr. Goniometer will be used to determine target angles. To measure plantarflexion and dorsiflexion muscular strength and endurance will be used with the isokinetic system. Weight-Bearing Lunge test will be used to evaluate ankle mobility. For balance assessment, the Modified Star Excursion Balance Test will be measured using the anterior, posteromedial and posterolateral directions. American Orthopedic Foot and Ankle Society midfoot score and foot and ankle functions Rating Foot and Ankle Outcome Score , which are subjective evaluation methods, will be used to determine the functional level. A heel lift test will be performed to evaluate physical performance.
Study: NCT06051227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Subjects receive one dose of study medication (fentanyl or esketamine) at baseline, either intravenous or intranasal
Study: NCT06179888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT and/or CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT and/or CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Given PO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Monitoring
Description: Undergo disease monitoring

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skeletal Survey X-Ray
Description: Undergo skeletal survey x-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skeletal Survey X-Ray
Description: Undergo skeletal survey x-ray
Study: NCT06132893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-7000
Description: BHV-7000 25 mg. Participants will take blinded investigational product (IP) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-7000
Description: BHV-7000 50 mg. Participants will take blinded investigational product (IP) once daily
Study: NCT05196919

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: XT-150 is a plasmid Deoxyribonucleic acid (DNA) formulated in buffered, D mannose saline solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: XT-150 is a plasmid Deoxyribonucleic acid (DNA) formulated in buffered, D mannose saline solution.
Study: NCT05783310

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation Intervention
Description: The participants in the intervention group will receive six sessions of psychoeducation intervention, lasting 60 minutes per session for six weeks. The intervention will be provided face-to-face using lectures and discussions. There will also be sharing of experience by the caregivers of children with cancer and a sharing by a caregiver of a childhood cancer survivor. The group format has been chosen to enable caregivers to offer emotional support to each other. The intervention has four components: cancer education, coping skills training, stress management techniques training, and psychological support. The intervention group will also receive the usual care.
Study: NCT05196919

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate-buffered saline for injection
Study: NCT04895982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular Injection
Study: NCT05055804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELG
Description: The effectiveness of ELG to standardized blood test methods (fingerstick) and comparison to AlcNOW + (or equivalence) and of laboratory test results.~Human subject requirements during ELG study will not challenge diabetics or non-diabetics glycemic event. For example, diabetes type 1, the subject will not have to adjust their insulin or glucose. For type 2 diabetes, the subject will not have to adjust their oral hypoglycemic agent or glucose, as well.
Study: NCT06528704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventilation feedback device
Description: Device showing delivered ventilation frequency and volume.
Study: NCT05554705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle intervention
Description: 12 week therapeutic lifestyle change program
Study: NCT05715593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health education intervention
Description: health education intervention
Study: NCT06579781

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Morehouse Family Health Study's Parent Toolkit 2.0
Description: Parent Toolkit 2.0 is designed to equip parents and caregivers with skills to talk to their teens about sex and contraception and ultimately influence their teens' decision-making and behaviors around sex. The Georgia Campaign for Adolescent Power \& Potential (GCAPP) developed the Parent Toolkit intervention. Morehouse School of Medicine's (MSM) Health Promotion Research Center tested and adapted it through an OPA Innovation Network grant, creating Parent Toolkit 2.0.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Morehouse Family Health Study's General Health Guide
Description: General Health Guide provides information to parents on how to promote health in their families.
Study: NCT05526430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harmine Hydrochloride Capsules
Description: capsules taken orally
Study: NCT04791748

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular tests
Description: Screening vestibular test for patients without chronic vestibular deficits Complete vestibular test if not done yet in care of patients with chronic vestibular deficits
Study: NCT06572891

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary obturator
Description: conventional acrylic obturator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implant supported obturator
Description: Implants inserted as planned The necks of the implants were bent up to 15 degrees to be parallel.~* The maxillary obturator was adjusted on the poured mode, modified and access holes will be made above the abutment to be finally relined in the patient mouth at the correct vertical dimension of occlusion to allow for immediate loading protocol.~* Impressions were made
Study: NCT05680480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept 240 mg
Description: Participants will receive Telitacicept 240mg weekly in addition to SOC for 48 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept 160 mg
Description: Participants will receive Telitacicept 160mg weekly in addition to SOC for 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo weekly in addition to SOC for 48 weeks.
Study: NCT06090864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Subjects will receive a lymphodepletion regimen of bendamustine 70 mg/m2 IV and fludarabine 30 mg/m2 each as a daily infusion for 3 consecutive days prior to the ATLCAR.CD30.CCR4 cell infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell infusion
Description: ATLCAR.CD30.CCR4 cells infusion for the eligible subjects after depletion chemotherapy.
Study: NCT06053112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New infant formula with 6 HMOs blend
Description: Infants are fed with HMO formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant formula without 6 HMOs blend
Description: Infants are fed with standard formula from the date of enrollment to the age of 6 months, exclusive formula feeding until the age of 4 months.
Study: NCT05952011

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left stellate ganglion block
Description: patients will be positioned with head in midline position and mild extension of the neck. Cricoid cartilage will be identified by midline palpation of the neck and a 12 mega hertz ultrasound probe will be used. The airway will be identified by the shadow of the cricoid cartilage at the level of C6 vertebrae. The probe will be moved laterally to identify internal jugular vein, carotid artery and thyroid. Depth of ultrasound field will be adjusted to include the transverse process of the C6 vertebra. Following complete aseptic precautions, an echogenic insulated needle 5 cm long will be inserted under ultrasound guidance and directed toward the transverse process of the C6 vertebra. After the needle tip will make contact with the transverse process, it will be withdrawn 2 mm and 8 ml of 0.25% bupivacaine will be injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Left stellate ganglion block
Description: patients will be positioned with head in midline position and mild extension of the neck. Cricoid cartilage will be identified by midline palpation of the neck and a 12 mega hertz ultrasound probe will be used. The airway will be identified by the shadow of the cricoid cartilage at the level of C6 vertebrae. The probe will be moved laterally to identify internal jugular vein, carotid artery and thyroid. Depth of ultrasound field will be adjusted to include the transverse process of the C6 vertebra. Following complete aseptic precautions, an echogenic insulated needle 5 cm long will be inserted under ultrasound guidance and directed toward the transverse process of the C6 vertebra. After the needle tip will make contact with the transverse process, it will be withdrawn 2 mm and 8 ml of 0.25% bupivacaine will be injected.
Study: NCT05901480

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OTOV101N+OTOV101C Injections
Description: The gene therapy of OTOV101N+OTOV101C injection via intracochlear injection.
Study: NCT04886544

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YVOIRE Y-Solution 720
Description: Hyaluronic acid dermal filler
Study: NCT06561880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Induction therapy regimen(2 courses):~triple regimen therapy: Azacitidine 75mg/m2/d d1-7; Venetoclax 100mg d1,200mg d2,400mg d3-28; Gilteritinib (as required at admission: 80 or 120mg) d1-28.~dose-adjusted triple regimen therapy: Azacitidine 75mg/m2/d d1-5; Venetoclax 400mg d1-7; Gilteritinib (as required at admission: 80 or 120mg) d1-28.~Patients with no remission after the first induction course will receive another course with triple regimen therapy; Patients with complete remission after the first induction course will receive another course of dose-adjusted triple regimen therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Consolidation therapy (3 courses):~intermediate-dose cytarabine regimen :2g/m2 q12h d1-3, age \< 60 years;1g/m2 q12h d1-3, age ≥60 years.~If NGS detected FLT3 mutation before consolidation chemotherapy, gilteritinib will be added during the consolidation course at d4-17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Maintenance treatment (6 courses):~dose-adjusted triple regimen therapy:Azacitidine 75mg/m2/d d1-5; Venetoclax 400mg d1-7; Gilteritinib (as required at admission: 80 or 120mg) d1-28.
Study: NCT05419128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PartnerCHESS
Description: The following ABCT services, from PartnerCHESS, will be available in the FamCHESS-C app but not in ACHESS-C:~ABCT tutorials. Interactive e-learning modules explaining key ABCT skills. Agreements between drinker and partner to follow key principles. Trigger identification and removal. Cravings discussion. Relapse plan. Reminders.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ACHESS
Description: ACHESS-C offers the following, which are also available in FamCHESS-C: Covid content, Instant Library, Discussion Groups, Personal Stories, Location Monitor, Surveys and Ecological Momentary Assessments, Guided Relaxation, Healthy Activities, Crisis Button, Skills Reminders
Study: NCT05056922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-PCIT
Description: Families randomized to Tele-PCIT will receive a time-limited version of PCIT via telehealth. The first 5 sessions focus on the child directed interaction (CDI) phase. The first session includes a teaching session where the parent will learn PRIDE/Do skills and Don't skills. The next 4 CDI sessions include coaching where the therapist coaches the parent on the these skills within the context of play. The first PDI session includes a teaching session where parents will be given instructions for providing commands and timeout procedures. During the 4 PDI coaching sessions, the therapist coaches the parent through timeout procedures. Handouts are emailed to families throughout therapy. The treatment period is 12 weeks to complete the 10 sessions to account for scheduling challenges. Families will be provided a Bluetooth headset for sessions. Families who do not have access to a computer, tablet, or smartphone with internet access will be provided with a tablet for therapy use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Families randomized to Treatment-as-Usual (TAU) will receive brief feedback and psychoeducation during the baseline visit and will be provided with community resources and referrals as needed. The TAU procedures will reflect the level of care families receive after an ASD assessment or professional consultation in our own clinic. For addressing behavioral concerns specifically, families will be provided handouts on behavior management tips, given access to a webinar workshop reviewing basic behavioral parenting principles, and instructed to engage with available services. The Vanderbilt Treatment \& Research Institute for ASD (TRIAD) Center offers a webinar series for managing challenging behaviors that parents will be directed to along with the Autism Speaks Challenging Behavior Toolkit handouts. The TAU period will be 12 weeks in length to match time specifications for the active treatment condition.
Study: NCT06375473

Intervention type: DRUG
Intervention: Irinotecan liposome II combination therapy regimen
Description: Irinotecan liposome II combination therapy regimen
Study: NCT05352061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Syndemics and Adherence Factors
Description: Each hour-long session is conducted via zoom or in person with a study clinician. Sessions focus on HIV medication adherence, coping with life stressors, and managing other challenging situations (e.g., possible traumatic experiences, drug and alcohol use and sexual behavior) that may affect mental or HIV-related health.
Study: NCT06419556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Plexus Block
Description: The patient's head was rested on a pillow and turned to the opposite side. A linear probe with higher frequencies was placed transversely over the midpoint of the SCM muscle. The carotid artery was identified and traced upwards to its bifurcation. the probe was then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle was advanced underneath the investing fascia of SCM muscle and above the interscalene groove until the pop on piercing the investing fascia was felt.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical Plexus Block
Description: The patient's head was rested on a pillow and turned to the opposite side. A linear probe with higher frequencies was placed transversely over the midpoint of the SCM muscle. The carotid artery was identified and traced upwards to its bifurcation. the probe was then moved laterally to identify the tapering posterolateral end of the SCM muscle. Via an in-plane technique, a 22-gauge, 50 mm needle was advanced underneath the investing fascia of SCM muscle and above the interscalene groove until the pop on piercing the investing fascia was felt.
Study: NCT05066594

Intervention type: DEVICE
Intervention: Transoral incisionless fundoplication
Description: The intervention of transoral incisionless fundoplication using the EsophyX (EndoGastric Solutions) system allows, through the endoscopic route, the creation of a cardial neovalve of approximately 270 ° by placing 20-28 polyethylene sutures on the cardial circumference, resulting in an anti-reflux plastic functionally similar to that obtained with the surgical fundoplication.